title: Interferon lambda 4 polymorphism affects on outcome of telaprevir, pegylated interferon and ribavirin combination therapy for chronic hepatitis C.
abstract: OBJECTIVE
  The predictive value of the recently identified interferon-λ (IFNL)4 polymorphism on the outcome of telaprevir (TVR), pegylated interferon (PEG IFN) plus ribavirin (RBV) combination therapy for chronic hepatitis C is unknown.
  
  
  METHODS
  We assessed predictive factors for sustained virological response (SVR) for TVR, PEG IFN plus RBV combination therapy in 283 genotype 1 chronic hepatitis C patients. IFNL4 polymorphism ss469415590 was analyzed by Invader assay.
  
  
  RESULTS
  SVR rates for patients with IFNL4 TT/TT genotype were significantly higher than for those with the IFNL4 TT/ΔG or ΔG/ΔG genotypes (93% and 59%, respectively, P < 0.0001). In a multivariate regression analysis, prior treatment history (treatment-naïve patients or patients who relapsed during prior treatment) (odds ratio [OR], 2.385; P = 0.028), rapid virological response (OR, 6.800; P < 0.0001) and ss469415590 TT/TT genotype (OR, 8.064; P < 0.0001) were identified as significant independent predictors for SVR. In patients with IFNL4 TT/ΔG or ΔG/ΔG genotypes, SVR rates for non-RVR patients were significantly lower than RVR patients (22% and 75%, respectively, P < 0.0001).
  
  
  CONCLUSIONS
  Analysis of IFNL4 polymorphism is a valuable predictor in patients receiving TVR triple therapy.
authors.affiliation: Department of Gastroenterology and Metabolism, Applied Life Science, Institute of Biomedical & Health Science, Hiroshima University, Hiroshima, Japan.
authors.forename: Yuko
authors.initials: Y
authors.lastname: Nagaoki
authors.forename: Michio
authors.initials: M
authors.lastname: Imamura
authors.forename: Yoshiiku
authors.initials: Y
authors.lastname: Kawakami
authors.forename: Hiromi
authors.initials: H
authors.lastname: Kan
authors.forename: Hatsue
authors.initials: H
authors.lastname: Fujino
authors.forename: Takayuki
authors.initials: T
authors.lastname: Fukuhara
authors.forename: Tomoki
authors.initials: T
authors.lastname: Kobayashi
authors.forename: Atsushi
authors.initials: A
authors.lastname: Ono
authors.forename: Takashi
authors.initials: T
authors.lastname: Nakahara
authors.forename: Noriaki
authors.initials: N
authors.lastname: Naeshiro
authors.forename: Ayako
authors.initials: A
authors.lastname: Urabe
authors.forename: Satoe
authors.initials: S
authors.lastname: Yokoyama
authors.forename: Daisuke
authors.initials: D
authors.lastname: Miyaki
authors.forename: Eisuke
authors.initials: E
authors.lastname: Murakami
authors.forename: Tomokazu
authors.initials: T
authors.lastname: Kawaoka
authors.forename: Masataka
authors.initials: M
authors.lastname: Tsuge
authors.forename: Akira
authors.initials: A
authors.lastname: Hiramatsu
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Aikata
authors.forename: Shoichi
authors.initials: S
authors.lastname: Takahashi
authors.forename: C Nelson
authors.initials: CN
authors.lastname: Hayes
authors.forename: Hidenori
authors.initials: H
authors.lastname: Ochi
authors.forename: Kazuaki
authors.initials: K
authors.lastname: Chayama
keywords: chronic hepatitis C; inteferon lambda 4; rapid virological response; sustained virological response; telaprevir